BioSpace News Archive

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Zentalis® Pharmaceuticals, Inc. announced that on January 2, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 6,250 shares of the Company’s common stock to two newly hired employees.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia’s common stock on December 29, 2023, as inducements material to such employee entering into employment with Akebia.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024 at 2:15 p.m. ET.

AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, announced the dates and times of quarterly conference calls for the year.

Bluejay Diagnostics, Inc. announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

Graviton Bioscience announced completion of financing from Enavate Sciences, a portfolio company of Patient Square Capital.

Seelos Therapeutics, Inc. announced that Institutional Shareholder Services, a leading independent proxy voting and corporate governance advisory firm, recommends Seelos stockholders vote “FOR” all proposals at the Special Meeting of Stockholders, including management’s proposal to increase the number of authorized shares of common stock.